From an article by Scott Wagers MD:
A challenge that anyone working to bring new technology, therapies, or approaches from proof of concept to clinic implementation is funding. I have been tracking the concept of crowd funding for a number of years, but have not seen many platforms that offer the opportunity to raise funding to a degree that will really make a difference.
So, I was enthusiastic when I met Pilar Puig Sàrries and learned about the work she is doing at Capital Cell, a crowdfunding platform specializing in the life sciences. She is the head the BioExpert Network and life sciences analytics at Capital Cell and passionate about her work to help startups in the life sciences bridge the translational gap.
How did you start doing what you are doing now?
During my PhD in molecular biology I felt uncertain about becoming a Spanish researcher because in Spain every 1-3 years you need to apply for further support for your research which means no stability.
So, during my PhD I began my first startup. It was an online/offline game for couples. I was able to sell 1.000 games after closing a successful crowdfunding campaign, which in my mind was pretty successful. But I also had to write my thesis and I also had a big interest in travel.
After my PhD I took a 9 month trip to South America and those 9 months were the happiest time of my life. When I came back, I knew that I didn’t want to keep doing research, so it seemed ideal to do something related to science, but also related to entrepreneurship. I was fortunate to find an opportunity at Capital Cell as a life science analyst.
What do you do at Capital Cell?
Capital cell is a start-up which means anyone working there has many roles. My job title is life science analyst, but I also do business development for clients such as helping them with their business models and building their pitch. We also help them look for investors as well. I also produce content for the website. Last year with the CEO of Capital Cell we created the BioExpert Network which is a network of experts who help us evaluate and select companies to be included in our crowdfunding platform.
Can you explain a bit about the philosophy behind Capital Cell and how it works?
Capital Cell is the first equity crowdfunding specialized in life sciences in Europe. And since last September, we are also operating in the UK.
We help companies in the life science sector get funded. Most of them are in the ‘valley of death’, which is also called the translational gap. They may have proof of concept, but need capital to continue to get scientific validation. We are now working with some companies that are further along, but still need to have some more funding before approaching VCs.
Image Credit: Shutterstock.com
News This Week
Scientists Develop Spray-On Powder That Instantly Seals Life-Threatening Wounds
KAIST scientists have created a fast-acting, stable powder hemostat that stops bleeding in one second and could significantly improve survival in combat and emergency medicine. Severe blood loss remains the primary cause of death from [...]
Oceans Are Struggling To Absorb Carbon As Microplastics Flood Their Waters
New research points to an unexpected way plastic pollution may be influencing Earth’s climate system. A recent study suggests that microscopic plastic pollution is reducing the ocean’s capacity to take in carbon dioxide, a [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from Frank Boehm
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
New Book! NanoMedical Brain/Cloud Interface – Explorations and Implications
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artificial Intelligence
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
Miller School Researchers Pioneer Nanovanilloid-Based Brain Cooling for Traumatic Injury
A multidisciplinary team at the University of Miami Miller School of Medicine has developed a breakthrough nanodrug platform that may prove beneficial for rapid, targeted therapeutic hypothermia after traumatic brain injury (TBI). Their work, published in ACS [...]
COVID-19 still claims more than 100,000 US lives each year
Centers for Disease Control and Prevention researchers report national estimates of 43.6 million COVID-19-associated illnesses and 101,300 deaths in the US during October 2022 to September 2023, plus 33.0 million illnesses and 100,800 deaths [...]
Nanomedicine in 2026: Experts Predict the Year Ahead
Progress in nanomedicine is almost as fast as the science is small. Over the last year, we've seen an abundance of headlines covering medical R&D at the nanoscale: polymer-coated nanoparticles targeting ovarian cancer, Albumin recruiting nanoparticles for [...]








Leave A Comment